Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial (2025) Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, et al. Journal article A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial (2025) Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, et al. Journal article Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial (2025) Powles T, Tagawa S, Vulsteke C, Gross-Goupil M, Park SH, Necchi A, De Santis M, et al. Journal article The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study (2025) Rangelova E, Stoop TF, van Ramshorst TM, Ali M, van Bodegraven EA, Javed AA, Hashimoto D, et al. Journal article Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial (2025) Bergmann L, Albiges L, Ahrens M, Gross-Goupil M, Boleti E, Gravis G, Fléchon A, et al. Journal article Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 (2024) Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kümmel S, et al. Journal article Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial (2023) Harbeck N, Fasching P, Wuerstlein R, Degenhardt T, Lüftner D, Kates RE, Schumacher J, et al. Journal article Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study (2023) Curigliano G, Dunton K, Rosenlund M, Janek M, Cathcart J, Liu Y, Fasching P, Iwata H Journal article Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response (2022) Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, Furlanetto J, et al. Journal article Risk-adapted modulation through deintensification of cancer treatments: an ESMO classification (2022) Hannoun-Levi JM, Gutierrez C, Polgar C, Strnad V Journal article